A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer
Status:
Withdrawn
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
Protocol AMP-024 is a Phase 2 study of imexon plus docetaxel for patients with previously
treated lung cancer that has spread in the body. Docetaxel is approved by the Food and Drug
Administration (FDA) as a second line therapy for this cancer. The imexon is administered on
days 1-5 and the docetaxel on day 1 of every 3 week cycle. The objective of the protocol is
to determine if the combination of imexon plus docetaxel is safe and effective.